Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Medial epicondylectomy plus oral steroids vs oral steroids alone Proportion of ulnar nerves with motor improvement after one year · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | RR 0.91 [0.64, 1.28] | 1 study · 62 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in sensory score after two years · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in motor score after two years · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Intervention NR Incidence of clinical neuropathy after 5 years: risk ratio · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | RR 0.46 [0.33, 0.63] | 3 studies · 1228 participants | High |
Intervention NR Annual change in vibration threshold in the feet · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 1 study · 99 participants | Moderate |
Intervention NR Death · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | RR 1.26 [1.06, 1.51] | 1 study · 10251 participants | High |
Intervention NR Weight gain · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | RR 1.96 [1.81, 2.13] | 1 study · 10078 participants | High |
Intervention NR Other adverse events · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Annual change in peroneal nerve motor conduction velocity m/sec · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 4 studies · 1371 participants | High |
Intervention NR Annual change in median nerve motor conduction velocity · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 2 studies · 1241 participants | High |
Intervention NR Annual change in ulnar nerve motor conduction velocity · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 2 studies · 134 participants | Moderate |
Intervention NR Annual change in vibration threshold in the feet · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 3 studies · 177 participants | High |
Intervention NR Adverse events · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Wide 95% CI. · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR Annual incidence of clinical neuropathy: risk ratio · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 4 studies · 6669 participants | High |
Intervention NR Annual change in median nerve motor conduction velocity · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | 1 study · 99 participants | Moderate |
Intervention NR "Substantial" benefit At least 50% reduction in pain or equivalent · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 412 participants | Low |
Intervention NR "Moderate" benefit At least 30% reduction in pain · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 715 participants | Low |
Intervention NR Proportion below 30/100 mm on VAS · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient global impression much or very much improved · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 715 participants | Moderate |
Intervention NR Quality of life measure · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse event withdrawals · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 874 participants | Moderate |
Intervention NR Serious adverse events · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 1304 participants | Moderate |
Intervention NR Death · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | 400 participants | Ungraded |
Ergonomic keyboard vs placebo Short‐term overall improvement ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Adverse effects ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Short‐term improvement in CTS symptoms (pain) (3 months or less) ‐ At end of 12 weeks treatment (Protouch Keyboard) Scale: 0 to 10 · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Ergonomic keyboard vs placebo Short‐term improvement in functional ability (3 months or less) (Protouch Keyboard) Scale: 13 to 65 · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Ergonomic keyboard vs placebo Long‐term improvement in CTS symptoms (pain ) from baseline to end of 6 months treatment (Apple Adjustable Keyboard) Scale: 0 to 10 · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | Very low |
Ergonomic keyboard vs placebo Long‐term improvement in functional ability (> 3 months) ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Neurodynamic mobilisation vs no treatment Short‐term overall improvement (three months or less) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | RR 15 [1.02, 220.92] | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Adverse effects · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Short‐term improvement in CTS symptoms (VAS pain) (three months or less) Scale from: 0 to 5 · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Short‐term improvement in functional ability or health‐related quality of life (hand function) (three months or less) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | RR 9 [0.59, 137.65] | 1 study · 12 participants | Very low |
Neurodynamic mobilisation vs no treatment Short‐term improvement in neurophysiologic parameters (three months or less) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Long‐term improvement in CTS symptoms (more than three months) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Long‐term improvement in functional ability or health‐related quality of life (more than three months) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Neurodynamic mobilisation vs no treatment Need for surgery · People with carpal tunnel syndrome on a waiting list for carpal tunnel release Exercise and mobilisation interventions for carpal tunnel syndrome (2012) · Cochrane | RR 0.33 [0.1, 1.12] | 1 study · 14 participants | Very low |
3,4‐Diaminopyridine vs placebo Improvement in muscle strength (QMG score) Scale from: 0 to 39 · participants with Lambert‐Eaton myasthenic syndrome Treatment for Lambert‐Eaton myasthenic syndrome (2011) · Cochrane | no estimate extracted | 2 studies · 40 participants | Moderate |
3,4‐Diaminopyridine vs placebo Improvement in mean CMAP amplitude (mV) · participants with Lambert‐Eaton myasthenic syndrome Treatment for Lambert‐Eaton myasthenic syndrome (2011) · Cochrane | no estimate extracted | 4 studies · 94 participants | High |
3,4‐Diaminopyridine vs placebo Adverse events · participants with Lambert‐Eaton myasthenic syndrome Treatment for Lambert‐Eaton myasthenic syndrome (2011) · Cochrane | no estimate extracted | 4 studies · 42 participants | High |
Vaccination vs placebo Persistence of PHN among all subjects a numerical rating scale for pain1 · people at risk for postherpetic neuralgia Vaccination for preventing postherpetic neuralgia (2011) · Cochrane | RR 0.31 [0.18, 0.54] | 1 study · 38501 participants | High |
Vaccination vs placebo Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 · people at risk for postherpetic neuralgia Vaccination for preventing postherpetic neuralgia (2011) · Cochrane | RR 0.64 [0.38, 1.09] | 1 study · 957 participants | Moderate |
Vaccination vs placebo Deaths among all subjects during the whole study clinical · people at risk for postherpetic neuralgia Vaccination for preventing postherpetic neuralgia (2011) · Cochrane | RR 1 [0.91, 1.1] | 1 study · 38546 participants | High |
Vaccination vs placebo Serious adverse events among subjects in the adverse event substudy clinical manifestations · people at risk for postherpetic neuralgia Vaccination for preventing postherpetic neuralgia (2011) · Cochrane | RR 1.53 [1.03, 2.25] | 1 study · 6616 participants | High |
Night splinting vs no night splinting Change in ankle dorsiflexion range of motion Lidcome Template in degrees. Scale from: 0.36 to 31.28. · patients with patients with reduced ankle range of motion in neuromuscular disease Interventions for increasing ankle range of motion in patients with neuromuscular disease (2010) · Cochrane | no estimate extracted | 2 studies · 52 participants | Very low |
Intervention NR improvement in the maintenance of wakefulness test · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy (2006) · Cochrane | no estimate extracted | 2 studies · 48 participants | Low |
Intervention NR improvement in the Epworth Sleepiness Score · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy (2006) · Cochrane | no estimate extracted | 4 studies · 101 participants | Low |
Intervention NR improvement in multiple sleep latency test · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy (2006) · Cochrane | no estimate extracted | 2 studies · 48 participants | Low |
Intervention NR quality of life scale ‐ mean improvement in total score of Short Form 36 · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy (2006) · Cochrane | no estimate extracted | 2 studies · 48 participants | Low |